Health Benefits
The FDA recently approved a new Eli Lilly drug, Zepbound (tirzepatide), for chronic weight management in adults with at least one weight-related health condition
9711, otherwise known as the Food and Drug Administration Act of 2009, the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use, promotion, advertising, or sponsorship of any health product without the proper authorization from the FDA is hereby prohibited
p = 0.98
Additionally, some patients experience increased urination while on GLP-1 medications
By stimulating both pathways simultaneously, the medication significantly slows down how quickly the stomach empties